Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 08, 2022

BUY
$72.62 - $79.98 $1.04 Million - $1.15 Million
14,357 New
14,357 $1.11 Million
Q4 2021

Jan 18, 2022

SELL
$53.63 - $62.52 $853,467 - $994,943
-15,914 Closed
0 $0
Q3 2021

Oct 18, 2021

BUY
$59.17 - $69.31 $941,631 - $1.1 Million
15,914 New
15,914 $942,000
Q2 2021

Jul 16, 2021

SELL
$61.91 - $67.42 $14,177 - $15,439
-229 Closed
0 $0
Q1 2021

Apr 09, 2021

SELL
$59.34 - $66.74 $214,039 - $240,731
-3,607 Reduced 94.03%
229 $14,000
Q4 2020

Jan 11, 2021

BUY
$57.74 - $65.43 $210,520 - $238,557
3,646 Added 1918.95%
3,836 $238,000
Q3 2020

Oct 23, 2020

SELL
$57.43 - $63.64 $1.71 Million - $1.89 Million
-29,774 Reduced 99.37%
190 $12,000
Q2 2020

Jul 13, 2020

BUY
$54.82 - $64.09 $1.09 Million - $1.27 Million
19,855 Added 196.41%
29,964 $1.82 Million
Q1 2020

Apr 14, 2020

BUY
$46.4 - $67.43 $463,675 - $673,827
9,993 Added 8614.66%
10,109 $563,000
Q4 2019

Jan 31, 2020

BUY
$49.21 - $64.19 $196 - $256
4 Added 3.57%
116 $7,000
Q3 2019

Oct 15, 2019

SELL
$42.77 - $50.71 $1,112 - $1,318
-26 Reduced 18.84%
112 $6,000
Q2 2019

Jul 18, 2019

SELL
$44.62 - $49.34 $252,192 - $278,869
-5,652 Reduced 97.62%
138 $6,000
Q1 2019

Apr 11, 2019

BUY
$45.12 - $53.8 $151,693 - $180,875
3,362 Added 138.47%
5,790 $276,000
Q4 2018

Jan 22, 2019

BUY
$48.76 - $63.23 $116,243 - $150,740
2,384 Added 5418.18%
2,428 $126,000
Q3 2018

Oct 23, 2018

BUY
$55.19 - $62.25 $772 - $871
14 Added 46.67%
44 $3,000
Q2 2018

Aug 01, 2018

BUY
$50.53 - $62.98 $1,515 - $1,889
30 New
30 $2,000
Q1 2018

May 02, 2018

SELL
$59.92 - $68.98 $115,945 - $133,476
-1,935 Closed
0 $0
Q4 2017

Feb 07, 2018

BUY
$59.94 - $65.35 $115,983 - $126,452
1,935
1,935 $119,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Nu Wave Investment Management, LLC Portfolio

Follow Nu Wave Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nu Wave Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nu Wave Investment Management, LLC with notifications on news.